Barclays Launches Equal-Weight Rating on Microchip's Preferred Stock ETF, Points to 6.90% Upside Potential

On February 13, 2026, Barclays initiated coverage of Microchip Technology Incorporated - Preferred Stock (NasdaqGS:MCHPP), assigning an Equal-Weight recommendation to this preferred stock offering. The rating reflects a balanced outlook where the research team sees moderate opportunity but also acknowledges significant headwinds. According to Barclays’ analysis published on February 4, 2026, investors may see potential gains of 6.90% based on current pricing levels.

Analyst Price Targets Suggest Measured Appreciation for Preferred Stock

The consensus price target among analysts for Microchip’s preferred stock stands at $73.55 per share as of early February 2026. Forecasts range widely from $52.85 on the conservative end to $86.99 on the bullish side. This average target price represents a 6.90% increase from the last reported closing price of $68.80 per share. The projected annual non-GAAP earnings per share (EPS) for the preferred stock is estimated at 1.27. While these forecasts indicate some upside potential, the wide range suggests analysts maintain divergent views on the preferred stock’s near-term trajectory.

Institutional Fund Positioning Shows Mixed Momentum

The preferred stock landscape reveals 132 funds and institutions currently holding positions in MCHPP. This represents a net decrease of 7 institutional holders, or 5.04%, compared to the previous quarter. The average portfolio weighting of all funds dedicated to this preferred stock stands at 0.36% of their respective holdings—an uptick of 1.01% from the prior quarter. Importantly, total institutional ownership grew by 0.09% to 51.723 million shares during the three-month period, suggesting that while some investors exited, those remaining increased their stakes.

Major Institutional Investors Adjust Holdings in MCHPP Preferred Stock

Capital International Investors, one of the largest institutional holders, now owns 13.881 million shares of the preferred stock. The firm previously reported 13.004 million shares, representing a 6.32% expansion in its position. More significantly, Capital International boosted its portfolio allocation to MCHPP by 2.32% over the past quarter, indicating a modest commitment increase.

AMRMX - American Mutual Fund also ramped up exposure, holding 4.333 million shares compared to 4.244 million previously—a 2.05% increase. This fund was far more aggressive, expanding its allocation in the preferred stock by 24.45%, suggesting greater conviction in the MCHPP opportunity.

In contrast, Voya Investment Management trimmed its holdings, reporting 3.890 million shares versus 4.703 million shares in prior filings—a notable 20.88% reduction in its preferred stock position. This pullback may reflect profit-taking or a shift in the fund’s preferred stock allocation strategy.

Other notable holders include CAIBX - Capital Income Builder with 3.411 million shares and ABALX - American Balanced Fund with 2.916 million shares, both of which maintained their positions unchanged during the quarter.

What This Means for Preferred Stock Investors

The mixed signals from analysts and the divergent moves by major institutional investors suggest caution may be warranted with MCHPP preferred stock. While some large players increased their bets, others scaled back exposure, reflecting legitimate disagreement about near-term prospects. Investors considering preferred stock exposure through ETF vehicles or direct holdings should weigh Barclays’ balanced stance alongside these fund-level positioning shifts.